Early development of immunity after hepatitis B vaccination is particularly important for patients such as hemophiliacs, at high risk for acquiring hepatitis B from potentially infectious plasmaderived concentrates. The purpose of this study was to evaluate whether or not protective antibody titers could be achieved quickly and maintained in hemophiliacs by an accelerated vaccination schedule. A yeast‐recombinant hepatitis B vaccine (Engerix B, SKF Ritt) was given subcutaneously in the deltoid region and repeated 2 and 6 weeks later to 85 hemophiliacs negative for hepatitis B virus (HBV) markers. After the first 22 patients had been enrolled, a modification of the schedule involving a fourth booster dose 24 weeks after the first dose of vaccine was applied to the next 63 consecutive vaccinees. Fifty‐three percent of vaccinees had antibody titers to hepatitis B surface antigen (anti‐HBs≥ 10 mlU/ml) by week 6, even though the mean titers of anti‐HBs were somewhat lower than those achieved historically in normal individuals. The protection rate had increased to 87% by week 10, one month after the third dose of vaccine, and to 93% by week 24. One year after starting vaccination, the rate for the vaccinees who did not receive the fourth booster dose was 71%, and 96% for those who did receive the fourth dose, with only 2 patients not responding despite the booster dose. It is concluded that even though the accelerated schedule of immunization produced rapidly high rates of protective antibody titers, a booster dose is required to obtain higher titers and provide more persistent immunity. Copyright © 1993 Wiley‐Liss, Inc., A Wiley Company
Accelerated schedule of hepatitis B vaccination in patients with hemophilia / Santagostino, E.; Mannucci, P. M.; Gringeri, A.; Rumi, M. G.; Rafanelli, D.; Rocino, A.; Schiavoni, M.; Chistolini, A.; Bona, E. D.; Muleo, G.. - In: JOURNAL OF MEDICAL VIROLOGY. - ISSN 0146-6615. - 41:2(1993), pp. 95-98. [10.1002/jmv.1890410202]
Accelerated schedule of hepatitis B vaccination in patients with hemophilia
Schiavoni M.;Chistolini A.;
1993
Abstract
Early development of immunity after hepatitis B vaccination is particularly important for patients such as hemophiliacs, at high risk for acquiring hepatitis B from potentially infectious plasmaderived concentrates. The purpose of this study was to evaluate whether or not protective antibody titers could be achieved quickly and maintained in hemophiliacs by an accelerated vaccination schedule. A yeast‐recombinant hepatitis B vaccine (Engerix B, SKF Ritt) was given subcutaneously in the deltoid region and repeated 2 and 6 weeks later to 85 hemophiliacs negative for hepatitis B virus (HBV) markers. After the first 22 patients had been enrolled, a modification of the schedule involving a fourth booster dose 24 weeks after the first dose of vaccine was applied to the next 63 consecutive vaccinees. Fifty‐three percent of vaccinees had antibody titers to hepatitis B surface antigen (anti‐HBs≥ 10 mlU/ml) by week 6, even though the mean titers of anti‐HBs were somewhat lower than those achieved historically in normal individuals. The protection rate had increased to 87% by week 10, one month after the third dose of vaccine, and to 93% by week 24. One year after starting vaccination, the rate for the vaccinees who did not receive the fourth booster dose was 71%, and 96% for those who did receive the fourth dose, with only 2 patients not responding despite the booster dose. It is concluded that even though the accelerated schedule of immunization produced rapidly high rates of protective antibody titers, a booster dose is required to obtain higher titers and provide more persistent immunity. Copyright © 1993 Wiley‐Liss, Inc., A Wiley CompanyI documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.